不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
T 细胞淋巴瘤患者感染预防推荐：叙述性综述与综合
英文原题：Recommendations on prevention of infections in patients with T-cell lymphomas: a narrative review and synthesis.
查看英文原题
Recommendations on prevention of infections in patients with T-cell lymphomas: a narrative review and synthesis.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
T/自然杀伤（NK）细胞淋巴瘤（TCL）是非霍奇金淋巴瘤中异质性较高的亚组，预后较差，治疗毒性也较高。目前缺乏对 TCL 患者感染结局的系统综述。国际指南尚未针对 TCL 患者的感染预防或支持性照护提出具体建议。本叙述性综述系统总结接受传统和新型疗法的 TCL 患者感染结局，并提出感染筛查、抗微生物药物预防和疫苗接种策略的建议。
展开英文摘要原文
T/Natural killer (NK) cell lymphomas (TCL) represent a heterogenous subgroup of non-Hodgkin lymphoma, associated with poorer prognosis and higher treatment toxicity. A cohesive synthesis of infection outcomes among TCL patients is lacking.
International guidelines offer no specific recommendations regarding prophylaxis or supportive infection care for TCL patients. This systematic narrative review highlights infection outcomes in TCL patients treated with conventional, and novel therapies. Recommendations for infection screening, antimicrobial prophylaxis and vaccination strategies are outined.
论文信息
- 作者
- Reynolds G、Anderson MA、Thursky K、Teh BW、Slavin MA
- 单位
- Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.Australia
- 文献类型
- 系统综述 · 非美国政府资助研究
- 期刊
- Leukemia & lymphoma2023 Dec
- 原文标识
- PubMed 37688482 · DOI 10.1080/10428194.2023.2252945